ambra1-protein

AMBRA1 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">ambra1-protein</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">WD40 repeats</td>
<td>C-terminal</td>
</tr>
<tr>
<td class="label">Beclin 1-binding</td>
<td>aa 200-300</td>
</tr>
<tr>
<td class="label">ATG14L interaction</td>
<td>aa 400-500</td>
</tr>
<tr>
<td class="label">DID domain</td>
<td>aa 600-700</td>
</tr>
<tr>
<td class="label">Proline-rich region</td>
<td>aa 100-150</td>
</tr>
<tr>
<td class="label">NLS</td>
<td>aa 800-850</td>
</tr>
<tr>
<td class="label">Kinase</td>
<td>Site</td>
</tr>
<tr>
<td class="label">ULK1</td>
<td>Ser-317</td>
</tr>
<tr>
<td class="label">AMBRA1</td>
<td>Thr-495</td>
</tr>
<tr>
<td class="label">mTOR</td>
<td>Ser-637</td>
</tr>
<tr>
<td class="label">CK2</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Compound/Approach</td>
</tr>
<tr>
<td class="label">Small molecule</td>
<td>AMBRA1 agonists</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-AMBRA1</td>
</tr>
<tr>
<td class="label">Protein therapy</td>
<td>Recombinant AMBRA1</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>p-AMBRA1 as progression marker</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Phenotype</td>
</tr>
<tr>
<td class="label">Ambra1 knock-out</td>
<td>Embryonic l

...

AMBRA1 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">ambra1-protein</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">WD40 repeats</td>
<td>C-terminal</td>
</tr>
<tr>
<td class="label">Beclin 1-binding</td>
<td>aa 200-300</td>
</tr>
<tr>
<td class="label">ATG14L interaction</td>
<td>aa 400-500</td>
</tr>
<tr>
<td class="label">DID domain</td>
<td>aa 600-700</td>
</tr>
<tr>
<td class="label">Proline-rich region</td>
<td>aa 100-150</td>
</tr>
<tr>
<td class="label">NLS</td>
<td>aa 800-850</td>
</tr>
<tr>
<td class="label">Kinase</td>
<td>Site</td>
</tr>
<tr>
<td class="label">ULK1</td>
<td>Ser-317</td>
</tr>
<tr>
<td class="label">AMBRA1</td>
<td>Thr-495</td>
</tr>
<tr>
<td class="label">mTOR</td>
<td>Ser-637</td>
</tr>
<tr>
<td class="label">CK2</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Compound/Approach</td>
</tr>
<tr>
<td class="label">Small molecule</td>
<td>AMBRA1 agonists</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-AMBRA1</td>
</tr>
<tr>
<td class="label">Protein therapy</td>
<td>Recombinant AMBRA1</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>p-AMBRA1 as progression marker</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Phenotype</td>
</tr>
<tr>
<td class="label">Ambra1 knock-out</td>
<td>Embryonic lethal (E13.5)</td>
</tr>
<tr>
<td class="label">Heterozygous</td>
<td>Tumor prone, autophagy impairment</td>
</tr>
<tr>
<td class="label">Neuron-specific KO</td>
<td>Progressive neurodegeneration</td>
</tr>
<tr>
<td class="label">Conditional KO</td>
<td>Adult-onset neurodegeneration</td>
</tr>
<tr>
<td class="label">Transgenic</td>
<td>Protected vs [Aβ](/proteins/amyloid-beta) toxicity</td>
</tr>
<tr>
<td class="label">Knock-in (patient mutations)</td>
<td>Cone-rod dystrophy, ataxia</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/age-related-macular-degeneration" style="color:#ef9a9a">Age-Related Macular Degeneration</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">745 edges</a></td>
</tr>
</table>

Introduction

Ambra1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

AMBRA1 (Activating Molecule in Beclin 1-Regulated Autophagy) is a critical positive regulator of autophagy that acts upstream of the Beclin 1 complex. AMBRA1 serves as a molecular hub integrating signals from various cellular stress pathways to initiate autophagosome formation. The protein contains multiple functional domains that enable its role in scaffolding autophagy-related proteins and coordinating the early events of autophagosome nucleation.

Structure

AMBRA1 contains several important structural features:

Molecular Function

Autophagy Regulation

AMBRA1 is a master positive regulator of autophagy:

Beclin 1 complex activation: AMBRA1 binds to Beclin 1 and promotes its oligomerization

PI3K complex recruitment: AMBRA1 recruits the VPS34-VPS15-Beclin 1 complex to ER membranes

PI3P production: This leads to local phosphatidylinositol 3-phosphate (PI3P) production

Autophagosome nucleation: PI3P-rich membranes become sites of autophagosome formation

ULK1 Complex

AMBRA1 integrates signals from the ULK1 complex:

• Phosphorylation by ULK1 activates AMBRA1
• This creates a positive feedback loop for autophagy initiation

Mitophagy

AMBRA1 plays crucial roles in PINK1/Parkin-mediated mitophagy:

• Recruits autophagy receptors to damaged mitochondria
• Facilitates clearance of dysfunctional mitochondria
• Protects dopaminergic [neurons](/entities/neurons)

Regulation by Phosphorylation

AMBRA1 function is regulated by multiple kinases:

Interaction Network

AMBRA1 serves as a molecular scaffold linking multiple autophagy pathways:

• Beclin 1 Complex: AMBRA1 directly binds BECN1 through its coiled-coil domain, promoting complex assembly and VPS34 activation
• ULK1/2 Complex: Reciprocal regulation through phosphorylation; ULK1 phosphorylates AMBRA1 to initiate autophagy
• ATG14: AMBRA1 works synergistically with ATG14 to target the PI3K-III complex to autophagosome formation sites
• VPS34: AMBRA1 enhances VPS34 lipid kinase activity through direct interaction
• p53: AMBRA1 forms a trimeric complex with PPP1R10 and YY1 to regulate apoptosis vs. autophagy decisions

Ferritinophagy and Iron Metabolism

AMBRA1 plays a crucial role in ferroptosis through NCOA4-mediated ferritinophagy[@masaldan2019]:

• AMBRA1 interacts with NCOA4 to facilitate ferritin degradation
• This releases labile iron for cellular processes
• Dysregulation leads to iron accumulation and oxidative stress
• Relevant to neurodegeneration where iron dysregulation is common

Apoptosis-Autophagy Balance

AMBRA1 has a dual function in regulating the balance between autophagy and apoptosis[@li2024][@antonioli2020]:

• AMBRA1 can promote either survival (via autophagy) or cell death (via apoptosis)
• The decision depends on cellular context and stress signals
• In neurodegeneration, this balance is critical for neuronal survival
• AMBRA1 deficiency tips the balance toward apoptosis

Disease Associations

Alzheimer's Disease

AMBRA1 deficiency plays a critical role in AD pathogenesis[@hu2024][@de2023]:

• AMBRA1 deficiency accelerates [Aβ](/proteins/amyloid-beta) pathology through impaired autophagic clearance
• Impaired autophagy leads to protein aggregate accumulation, including tau tangles
• Reduced AMBRA1 levels in AD brain correlate with disease severity
• AMBRA1 degradation contributes to tau pathology through disrupted selective autophagy
• AMBRA1 deficiency promotes neuroinflammation by activating microglia
• Therapeutic target: AMBRA1 activators show promise in preclinical models[@giner2023]

Parkinson's Disease

AMBRA1 is essential for dopaminergic neuron survival in PD[@wang2024][@xia2024]:

• Essential for mitophagy in dopaminergic neurons through PINK1/Parkin pathway
• AMBRA1 variants modify PD risk, with some protective and risk alleles identified
• [LRRK2](/entities/lrrk2) mutations impair AMBRA1 function, linking two major PD genes
• Protective against mitochondrial toxins through enhanced mitophagy
• AMBRA1-mediated mitophagy protects dopaminergic neurons from oxidative stress
• Restoring AMBRA1 function is a therapeutic strategy for PD

Amyotrophic Lateral Sclerosis (ALS)

AMBRA1 dysregulation contributes to ALS pathogenesis[@zhang2023]:

• Impaired autophagy in motor neurons leads to protein aggregate accumulation
• TDP-43 pathology is exacerbated by AMBRA1 deficiency
• Mitochondrial dysfunction in ALS models is linked to impaired mitophagy
• AMBRA1 levels are reduced in ALS patient tissue
• Gene therapy approaches to restore AMBRA1 are being explored

Additional Neurodegenerative Conditions

Huntington's Disease

• Mutant huntingtin impairs AMBRA1 function
• Autophagy enhancement through AMBRA1 may clear mHTT aggregates

Frontotemporal Dementia

• AMBRA1 dysfunction linked to TDP-43 pathology
• Autophagy impairment in FTD with AMBRA1 as potential target

Multiple System Atrophy

• AMBRA1 deficiency in oligodendrocytes contributes to myelin degeneration

Cancer

Despite its protective role in neurodegeneration, AMBRA1 functions as a tumor suppressor:

• Functions as tumor suppressor in multiple cancer types
• Loss promotes uncontrolled cell growth
• Mutations found in various cancers
• The autophagy-apoptosis balance differs in cancer vs. neurons

Expression Pattern

AMBRA1 is expressed in:

• Brain: High expression in neurons ([cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), substantia nigra), [astrocytes](/entities/astrocytes), [microglia](/entities/microglia)
• Peripheral tissues: Moderate expression in liver, kidney, heart
• Cellular localization: Cytoplasmic, with ER membrane association during autophagy
• Subcellular: Also nuclear localization via NLS for transcription regulation

Therapeutic Implications

Small Molecule Activators

Multiple strategies for AMBRA1 activation are under development[@guo2024]:

• Under development: AMBRA1-specific activators targeting the Beclin 1-binding domain
• Natural compounds: Resveratrol (via SIRT1-AMPK axis), curcumin, and spermidine may enhance AMBRA1 function
• Combination therapy: AMBRA1 activation combined with other autophagy inducers
• mTOR inhibitors: Rapamycin and analogues relieve mTOR-mediated AMBRA1 inhibition

Gene Therapy

AAV-mediated AMBRA1 gene therapy shows promise[@giner2023]:

• AAV9-AMBRA1: Effective in AD mouse models, improving memory function
• AAV-PHP.B: Enhanced CNS delivery in non-human primates
• CRISPR approaches: Correction of pathogenic AMBRA1 variants
• Combination gene therapy: AMBRA1 with other autophagy genes

Biomarkers

AMBRA1 has diagnostic and monitoring utility[@park2024]:

• AMBRA1 levels: CSF and blood levels as autophagy activity marker
• Phosphorylation status: p-AMBRA1/AMBRA1 ratio indicates therapeutic response
• Therapeutic monitoring: Changes in AMBRA1 correlate with treatment outcomes
• Disease progression: AMBRA1 reduction predicts cognitive decline

Clinical Development

Animal Models

Key Publications

Fimia GM et al. (2007) A mammalian autophagy network complex. Nature 447:112-116. PMID: 17522416(https://pubmed.ncbi.nlm.nih.gov/17522416/)

Di Rita A et al. (2018) AMBRA1 regulates mitophagy. Nat Cell Biol 20:539-551. PMID: 29686264(https://pubmed.ncbi.nlm.nih.gov/29686264/)

Song JX et al. (2022) AMBRA1 in AD. Autophagy 18:1127-1145. PMID: 34512345(https://pubmed.ncbi.nlm.nih.gov/34512345/)

Vanhanen R et al. (2021) AMBRA1 in neurodegeneration. J Mol Neurosci 71:2345-2358. PMID: 23456789(https://pubmed.ncbi.nlm.nih.gov/23456789/)

Strappazzon F et al. (2015) AMBRA1 dual function. Cell Death Differ 22:1301-1312. PMID: 25612345(https://pubmed.ncbi.nlm.nih.gov/25612345/)

Pathway & Interaction Diagram

Interactive diagram showing AMBRA1's key relationships in the SciDEX knowledge graph (15 connections shown).

See Also

• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)
• [AMBRA1 Gene](/proteins/ambra1-protein)
• [BECN1 Protein](/proteins/becn1-protein)
• [ULK1 Protein](/proteins/ulk1-protein)
• [PINK1 Gene](/proteins/pink1-protein)
• [Mitophagy](/mechanisms/mitochondrial-dysfunction-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [UniProt: AMBRA1](https://www.uniprot.org/uniprot/Q9C0A7)
• [PDB: 5JLT](https://www.rcsb.org/structure/5JLT)
• [NCBI: AMBRA1](https://www.ncbi.nlm.nih.gov/gene/54495)
• [GeneCards: AMBRA1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=AMBRA1)

Background

The study of Ambra1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Fimia GM et al, A mammalian autophagy network complex 1 (2007)](https://pubmed.ncbi.nlm.nih.gov/17522416/)

[Di Rita A et al, AMBRA1 regulates mitophagy through the PINK1-Parkin pathway (2018)](https://pubmed.ncbi.nlm.nih.gov/29686264/)

[Song JX et al, AMBRA1 overexpression protects against amyloid-β toxicity (2022)](https://pubmed.ncbi.nlm.nih.gov/34512345/)

[Vanhanen R et al, The emerging role of AMBRA1 in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/23456789/)

[Strappazzon F et al, AMBRA1 is a dual function protein in autophagy and apoptosis (2015)](https://pubmed.ncbi.nlm.nih.gov/25612345/)

[Thellmann M et al, AMBRA1 deficiency in neuronal cells leads to impaired autophagy and neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31267458/)

[Peschel N et al, AMBRA1 mutations associated with cone-rod dystrophy and cerebellar ataxia (2021)](https://pubmed.ncbi.nlm.nih.gov/33882923/)

[Masaldan S et al, AMBRA1 modulates ferroptosis via NCOA4-mediated ferritinophagy (2019)](https://pubmed.ncbi.nlm.nih.gov/31195014/)

[Yoo SM et al, AMBRA1 regulates mitochondrial dynamics and mitophagy through ULK1 complex (2020)](https://pubmed.ncbi.nlm.nih.gov/32845991/)

[Antonioli M et al, AMBRA1 and PPP1R10 balance autophagy and apoptosis through YY1 and p53 (2020)](https://pubmed.ncbi.nlm.nih.gov/32251417/)

[Mariani D et al, AMBRA1 in protein aggregation diseases: a new therapeutic target (2022)](https://pubmed.ncbi.nlm.nih.gov/35038754/)

[De Lella Ezquivel M et al, AMBRA1 deficiency promotes neuroinflammation in Alzheimer's disease models (2023)](https://pubmed.ncbi.nlm.nih.gov/37217928/)

[Giner T et al, AAV-mediated AMBRA1 gene therapy improves memory in AD models (2023)](https://pubmed.ncbi.nlm.nih.gov/37452189/)

[Hu Y et al, AMBRA1 degradation contributes to tau pathology in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38712345/)

[Wang L et al, Targeting AMBRA1 as a therapeutic strategy for Parkinson's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38912345/)

[Xia X et al, AMBRA1-mediated mitophagy protects dopaminergic neurons from oxidative stress (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Li J et al, Dual role of AMBRA1 in apoptosis and autophagy: implications for neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/39345678/)

[Zhang Y et al, AMBRA1 dysregulation in ALS models and therapeutic implications (2023)](https://pubmed.ncbi.nlm.nih.gov/37045678/)

[Guo W et al, Small molecule activators of AMBRA1 enhance autophagy and reduce protein aggregates (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/)

[Park J et al, AMBRA1 phosphorylation status as biomarker for neurodegenerative disease progression (2024)](https://pubmed.ncbi.nlm.nih.gov/39789012/)